Roche Holding AG (ROZ.XC)
| Previous close | 275.40 |
| Open | 275.00 |
| Bid | 273.60 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 273.00 - 275.80 |
| 52-week range | 229.80 - 298.40 |
| Volume | |
| Avg. volume | 2,592 |
| Market cap | 201.415B |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | 19.15 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 9.60 (3.49%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
- Globe Newswire
Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO)
Positive recommendation is based on two Phase III studies. In addition to robust retinal drying with Vabysmo, these data show early and sustained vision improvements, which are non-inferior to aflibercept If approved, Vabysmo would be the first and only bispecific antibody treatment available for the nearly one million people with RVO in the European UnionVabysmo is already approved in the US and Japan for RVO and in more than 95 countries around the world for people living with nAMD and DME Bas
- Globe Newswire
CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition
If approved, PiaSky will be the first monthly subcutaneous (SC) treatment for paroxysmal nocturnal haemoglobinuria (PNH) in the EU Additionally, with the option to self-administer, PiaSky may provide an alternative to existing intravenous (IV) C5 inhibitors, potentially helping to reduce treatment burden1The recommendation is based on the COMMODORE 2 study results, where SC PiaSky given every month demonstrated equivalent disease control and comparable safety to IV eculizumab given every two wee
- GlobeNewswire
Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection
The World Health Organization (WHO) has awarded Roche's human papillomavirus (HPV) test prequalification designations for use on the cobas 5800 System and for self-collected samples on the cobas 5800, 6800 and 8800 Systems. These designations build upon last June's WHO prequalification that included the cobas HPV test for use on the cobas 6800 and 8800 Systems.WHO prequalification enables low- and middle-income countries (LMICs) to use Roche HPV screening solutions, including self-collection, in
